Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987425231> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2987425231 endingPage "105841" @default.
- W2987425231 startingPage "105841" @default.
- W2987425231 abstract "β-lactam- and multi-drug-resistant (MDR) Gram-negative bacilli frequently cause lower respiratory tract infections (LRTIs) in patients housed in intensive care units (ICUs). Relebactam, a novel diazabicyclooctane inhibitor of Ambler class A and C β-lactamases, in combination with imipenem-cilastatin was approved by the US Food and Drug Administration in July 2019 for the treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections. A phase III study of imipenem/relebactam for the treatment of patients with respiratory tract infections, including antimicrobial-resistant Gram-negative infections, has also been completed. The Clinical and Laboratory Standards Institute's broth microdilution methodology was used to determine minimum inhibitory concentrations against non-Proteeae Enterobacteriaceae (NPE) and Pseudomonas aeruginosa collected from ICU patients with LRTIs at 26 US hospitals in 2015-2017. Percent susceptibilities to imipenem/relebactam were 97.0%, 66.4% and 98.1%, respectively, for all NPE (n=1298), imipenem-non-susceptible NPE (n=113, of which 71% were Serratia marcescens) and MDR NPE (n=206), and 92.2%, 77.2% and 79.6%, respectively, for all P. aeruginosa (n=638), imipenem-non-susceptible P. aeruginosa (n=219) and MDR P. aeruginosa (n=225). Percent susceptibilities to imipenem/relebactam were 98.0-98.6% for cefepime-, ceftazidime- and piperacillin-tazobactam-non-susceptible NPE and 77.8-82.5% for cefepime-, ceftazidime- and piperacillin-tazobactam-non-susceptible P. aeruginosa. Generally, only slight variations in susceptibility were observed across US census regions. Imipenem/relebactam may provide a valuable therapeutic option for the treatment of ICU patients with LRTI caused by Gram-negative bacilli resistant to commonly used β-lactams, as it demonstrated potent in-vitro activity against the majority of tested β-lactam-non-susceptible and MDR Gram-negative bacilli from ICU patients with LRTIs in US hospitals." @default.
- W2987425231 created "2019-11-22" @default.
- W2987425231 creator A5017159626 @default.
- W2987425231 creator A5038009031 @default.
- W2987425231 creator A5042149117 @default.
- W2987425231 creator A5061522332 @default.
- W2987425231 creator A5066677972 @default.
- W2987425231 creator A5089366807 @default.
- W2987425231 date "2020-01-01" @default.
- W2987425231 modified "2023-10-02" @default.
- W2987425231 title "In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017" @default.
- W2987425231 cites W1618166169 @default.
- W2987425231 cites W2087865186 @default.
- W2987425231 cites W2113957516 @default.
- W2987425231 cites W2149033372 @default.
- W2987425231 cites W2408072278 @default.
- W2987425231 cites W2807183168 @default.
- W2987425231 cites W2883194703 @default.
- W2987425231 cites W2889701556 @default.
- W2987425231 cites W2955048139 @default.
- W2987425231 cites W4229630274 @default.
- W2987425231 doi "https://doi.org/10.1016/j.ijantimicag.2019.10.022" @default.
- W2987425231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31704217" @default.
- W2987425231 hasPublicationYear "2020" @default.
- W2987425231 type Work @default.
- W2987425231 sameAs 2987425231 @default.
- W2987425231 citedByCount "24" @default.
- W2987425231 countsByYear W29874252312020 @default.
- W2987425231 countsByYear W29874252312021 @default.
- W2987425231 countsByYear W29874252312022 @default.
- W2987425231 countsByYear W29874252312023 @default.
- W2987425231 crossrefType "journal-article" @default.
- W2987425231 hasAuthorship W2987425231A5017159626 @default.
- W2987425231 hasAuthorship W2987425231A5038009031 @default.
- W2987425231 hasAuthorship W2987425231A5042149117 @default.
- W2987425231 hasAuthorship W2987425231A5061522332 @default.
- W2987425231 hasAuthorship W2987425231A5066677972 @default.
- W2987425231 hasAuthorship W2987425231A5089366807 @default.
- W2987425231 hasConcept C126322002 @default.
- W2987425231 hasConcept C176947019 @default.
- W2987425231 hasConcept C2776012195 @default.
- W2987425231 hasConcept C2776968632 @default.
- W2987425231 hasConcept C2777050379 @default.
- W2987425231 hasConcept C2777437143 @default.
- W2987425231 hasConcept C2777637488 @default.
- W2987425231 hasConcept C2778193466 @default.
- W2987425231 hasConcept C2778266534 @default.
- W2987425231 hasConcept C2779631663 @default.
- W2987425231 hasConcept C2780950330 @default.
- W2987425231 hasConcept C4937899 @default.
- W2987425231 hasConcept C501593827 @default.
- W2987425231 hasConcept C523546767 @default.
- W2987425231 hasConcept C534529494 @default.
- W2987425231 hasConcept C54355233 @default.
- W2987425231 hasConcept C71924100 @default.
- W2987425231 hasConcept C86803240 @default.
- W2987425231 hasConcept C89423630 @default.
- W2987425231 hasConcept C94665300 @default.
- W2987425231 hasConceptScore W2987425231C126322002 @default.
- W2987425231 hasConceptScore W2987425231C176947019 @default.
- W2987425231 hasConceptScore W2987425231C2776012195 @default.
- W2987425231 hasConceptScore W2987425231C2776968632 @default.
- W2987425231 hasConceptScore W2987425231C2777050379 @default.
- W2987425231 hasConceptScore W2987425231C2777437143 @default.
- W2987425231 hasConceptScore W2987425231C2777637488 @default.
- W2987425231 hasConceptScore W2987425231C2778193466 @default.
- W2987425231 hasConceptScore W2987425231C2778266534 @default.
- W2987425231 hasConceptScore W2987425231C2779631663 @default.
- W2987425231 hasConceptScore W2987425231C2780950330 @default.
- W2987425231 hasConceptScore W2987425231C4937899 @default.
- W2987425231 hasConceptScore W2987425231C501593827 @default.
- W2987425231 hasConceptScore W2987425231C523546767 @default.
- W2987425231 hasConceptScore W2987425231C534529494 @default.
- W2987425231 hasConceptScore W2987425231C54355233 @default.
- W2987425231 hasConceptScore W2987425231C71924100 @default.
- W2987425231 hasConceptScore W2987425231C86803240 @default.
- W2987425231 hasConceptScore W2987425231C89423630 @default.
- W2987425231 hasConceptScore W2987425231C94665300 @default.
- W2987425231 hasIssue "1" @default.
- W2987425231 hasLocation W29874252311 @default.
- W2987425231 hasLocation W29874252312 @default.
- W2987425231 hasOpenAccess W2987425231 @default.
- W2987425231 hasPrimaryLocation W29874252311 @default.
- W2987425231 hasRelatedWork W1603357412 @default.
- W2987425231 hasRelatedWork W2116303484 @default.
- W2987425231 hasRelatedWork W2354228318 @default.
- W2987425231 hasRelatedWork W2371368961 @default.
- W2987425231 hasRelatedWork W2396923746 @default.
- W2987425231 hasRelatedWork W2604212113 @default.
- W2987425231 hasRelatedWork W2800457509 @default.
- W2987425231 hasRelatedWork W2987425231 @default.
- W2987425231 hasRelatedWork W3024309290 @default.
- W2987425231 hasRelatedWork W4242790524 @default.
- W2987425231 hasVolume "55" @default.
- W2987425231 isParatext "false" @default.
- W2987425231 isRetracted "false" @default.
- W2987425231 magId "2987425231" @default.
- W2987425231 workType "article" @default.